VivoSeq
Immunology

Inclusion Body Myositis

15

Pipeline Programs↗

3

Active Trials↗

10

Companies Involved↗

Inclusion Body Myositis is an emerging landscape with 15 programs across 10 companies. The most active players are Biogen, Takeda, Immunex. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1I

Immunex

1 program

Phase 1H

Horizon Therapeutics Ireland DAC

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

11 of 15 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody320%Protein / enzyme17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed12 · 67%
Active, not recruiting2 · 11%
Withdrawn1 · 6%
Terminated1 · 6%
Recruiting1 · 6%
Unknown status1 · 6%

Clinical Trials

Trial Activity

18 trials

Ruxolitinib Treatment in Inclusion Body Myositis
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06536166·80 enrolled
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Active, not recruiting·AAbcuro, Inc.·Phase 2/3·NCT06450886·270 enrolled
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting·UUniversity of Kansas Medical Center·N/A·NCT06153108·20 enrolled
Blood-flow Restricted Exercise in Inclusion Body Myositis
Completed·UUniversity of Southern Denmark·N/A·NCT02317094·22 enrolled
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Completed·ZZevraDenmark·Phase 2·NCT02753530·152 enrolled
Study of Pioglitazone in Sporadic Inclusion Body Myositis
Completed·JJohns Hopkins University·Phase 1·NCT03440034·19 enrolled
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Completed·Novartis logoNovartis·Phase 2·NCT01423110·14 enrolled
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2/3·NCT02481453·44 enrolled
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
Completed·UUniversity of Kansas Medical Center·Phase 1·NCT04421677·10 enrolled
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Completed·WWashington University School of Medicine·Phase 1·NCT00802815·20 enrolled
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00079768·20 enrolled
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Completed·Novartis logoNovartis·Phase 2/3·NCT02250443·10 enrolled
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Completed·Novartis logoNovartis·Phase 3·NCT02573467·211 enrolled
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Completed·AAbcuro, Inc.·Phase 2/3·NCT05721573·272 enrolled
Arimoclomol in Sporadic Inclusion Body Myositis
Completed·—·Phase 2/3·NCT00769860·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)